These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2645 related items for PubMed ID: 26181252

  • 1. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S.
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [Abstract] [Full Text] [Related]

  • 2. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO.
    JAMA Oncol; 2017 Nov 09; 3(11):e172085. PubMed ID: 28750133
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL.
    JAMA Oncol; 2016 Jan 09; 2(1):56-64. PubMed ID: 26469139
    [Abstract] [Full Text] [Related]

  • 5. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
    Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber RD, Piccart-Gebhart M, Di Cosimo S.
    Eur J Cancer; 2019 Sep 09; 118():169-177. PubMed ID: 31377477
    [Abstract] [Full Text] [Related]

  • 6. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N.
    Lancet Oncol; 2013 Nov 09; 14(12):1183-92. PubMed ID: 24095300
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
    Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, Campbell JD, Hoadley KA, Spears PA, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, Llombart-Cussac A, Prat A, Perou CM, Carey LA.
    JAMA Oncol; 2023 Apr 01; 9(4):490-499. PubMed ID: 36602784
    [Abstract] [Full Text] [Related]

  • 8. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N.
    Eur J Cancer; 2019 Sep 01; 118():41-48. PubMed ID: 31302586
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
    Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart MJ, Von Minckwitz G, Baselga J, Loi S.
    Eur J Cancer; 2017 Nov 01; 85():133-145. PubMed ID: 28923573
    [Abstract] [Full Text] [Related]

  • 10. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S, Duan X, Xu L, Xin L, Cheng Y, Liu Q, Ye J, Zhang S, Zhang H, Zhu S, Li T, Liu Y.
    Breast Cancer Res Treat; 2015 Nov 01; 154(2):239-49. PubMed ID: 26498019
    [Abstract] [Full Text] [Related]

  • 11. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E.
    Ann Oncol; 2018 Jan 01; 29(1):170-177. PubMed ID: 29045543
    [Abstract] [Full Text] [Related]

  • 12. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M.
    Cancer Treat Rev; 2017 Jun 01; 57():8-15. PubMed ID: 28525810
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ, Zhang Y, Li N, Liu PJ, Gao L, Gao X, Tie XJ.
    BMJ Open; 2017 Mar 13; 7(3):e013053. PubMed ID: 28289045
    [Abstract] [Full Text] [Related]

  • 14. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.
    Musolino A, Naldi N, Dieci MV, Zanoni D, Rimanti A, Boggiani D, Sgargi P, Generali DG, Piacentini F, Ambroggi M, Cagossi K, Gianni L, Sarti S, Bisagni G, Ardizzoni A, Conte PF, Guarneri V.
    Pharmacogenomics J; 2016 Oct 13; 16(5):472-7. PubMed ID: 27378608
    [Abstract] [Full Text] [Related]

  • 15. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
    Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, NeoALTTO Study Team.
    Lancet; 2012 Feb 18; 379(9816):633-40. PubMed ID: 22257673
    [Abstract] [Full Text] [Related]

  • 16. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S.
    Lancet Oncol; 2017 Jan 18; 18(1):52-62. PubMed ID: 27964843
    [Abstract] [Full Text] [Related]

  • 17. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H.
    Lancet Oncol; 2015 Dec 18; 16(16):1700-10. PubMed ID: 26596672
    [Abstract] [Full Text] [Related]

  • 18. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
    Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J.
    Ann Oncol; 2015 Jul 18; 26(7):1494-500. PubMed ID: 25851628
    [Abstract] [Full Text] [Related]

  • 19. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
    Ingold Heppner B, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, Fasching PA, Tesch H, Solbach C, Rezai M, Zahm DM, Holms F, Glados M, Krabisch P, Heck E, Ober A, Lorenz P, Diebold K, Habeck JO, Loibl S.
    Clin Cancer Res; 2016 Dec 01; 22(23):5747-5754. PubMed ID: 27189162
    [Abstract] [Full Text] [Related]

  • 20. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S.
    Lancet Oncol; 2018 Jan 01; 19(1):40-50. PubMed ID: 29233559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 133.